Literature DB >> 18752049

Expression of tight junction protein claudin-4 in basal-like breast carcinomas.

Janina Kulka1, Attila Marcell Szász, Zsuzsanna Németh, Lilla Madaras, Zsuzsa Schaff, István Arthur Molnár, Anna-Mária Tokés.   

Abstract

Claudins (CLDN) are tight junction proteins which contribute to the paracellular transport and ionic permeability of various epithelia. In recent years they came into focus for their suggested role in carcinogenesis and possible role in cancer therapy. According to our previous studies, in breast tissue CLDN4 is also related to the level of cellular differentiation. Thirty-eight estrogen (ER) and progesterone receptor (PgR) negative, HER2/neu negative, but cytokeratin 5/6 positive basal-like-mainly grade 3-breast carcinomas were compared with twenty-one grade 1, twenty-five grade 2 and twenty grade 3 non-basal-like invasive breast carcinomas, in respect to their CLDN4 expression. The immunohistochemical reactions were evaluated both semiquantitatively and by morphometrical analysis. Statistically significant difference (p = 0.001) was observable regarding CLDN4 expression in the basal-like group as compared to grade 1 and 2 cancers. Further, CLDN4 expression was significantly higher (p = 0.017) in the basal-like compared with the non-basal-like grade 3 carcinomas. Our results suggest that basal-like carcinomas are a subset of breast cancer with high level of CLDN4 protein expression. The finding is in accordance with our former observation that CLDN4 is indeed related to cellular differentiation. This observation may be seen as a further proof that basal-like carcinomas represent a separable group amongst grade 3 breast carcinomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752049     DOI: 10.1007/s12253-008-9089-x

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  18 in total

Review 1.  Molecular classification of breast tumors: toward improved diagnostics and treatments.

Authors:  Therese Sørlie
Journal:  Methods Mol Biol       Date:  2007

2.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Authors:  Chad A Livasy; Gamze Karaca; Rita Nanda; Maria S Tretiakova; Olufunmilayo I Olopade; Dominic T Moore; Charles M Perou
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

3.  The expression of five different claudins in invasive breast carcinomas: comparison of pT1pN1 and pT1pN0 tumors.

Authors:  Anna-Mária Tokés; Janina Kulka; Sándor Paku; Miklós Máthé; Csilla Páska; Csaba Lódi; András Kiss; Zsuzsa Schaff
Journal:  Pathol Res Pract       Date:  2005       Impact factor: 3.250

4.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

5.  Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype.

Authors:  Stéphane Garcia; Jean-Philippe Dalès; Emmanuelle Charafe-Jauffret; Séverine Carpentier-Meunier; Lucile Andrac-Meyer; Jocelyne Jacquemier; Claudine Andonian; Marie-Noëlle Lavaut; Claude Allasia; Pascal Bonnier; Colette Charpin
Journal:  Hum Pathol       Date:  2007-02-20       Impact factor: 3.466

6.  Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma.

Authors:  Gábor Sobel; Csilla Páska; István Szabó; András Kiss; Anna Kádár; Zsuzsa Schaff
Journal:  Hum Pathol       Date:  2005-02       Impact factor: 3.466

7.  Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer.

Authors:  Patrick Michl; Claudia Barth; Malte Buchholz; Markus M Lerch; Monika Rolke; Karl-Heinz Holzmann; Andre Menke; Heiko Fensterer; Klaudia Giehl; Matthias Löhr; Gerhard Leder; Takeshi Iwamura; Guido Adler; Thomas M Gress
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

Review 8.  Demystifying basal-like breast carcinomas.

Authors:  L Da Silva; C Clarke; S R Lakhani
Journal:  J Clin Pathol       Date:  2007-05-11       Impact factor: 3.411

9.  The molecular portraits of breast tumors are conserved across microarray platforms.

Authors:  Zhiyuan Hu; Cheng Fan; Daniel S Oh; J S Marron; Xiaping He; Bahjat F Qaqish; Chad Livasy; Lisa A Carey; Evangeline Reynolds; Lynn Dressler; Andrew Nobel; Joel Parker; Matthew G Ewend; Lynda R Sawyer; Junyuan Wu; Yudong Liu; Rita Nanda; Maria Tretiakova; Alejandra Ruiz Orrico; Donna Dreher; Juan P Palazzo; Laurent Perreard; Edward Nelson; Mary Mone; Heidi Hansen; Michael Mullins; John F Quackenbush; Matthew J Ellis; Olufunmilayo I Olopade; Philip S Bernard; Charles M Perou
Journal:  BMC Genomics       Date:  2006-04-27       Impact factor: 3.969

10.  Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study.

Authors:  Anna-Mária Tokés; Janina Kulka; Sándor Paku; Agnes Szik; Csilla Páska; Pál Kaposi Novák; László Szilák; András Kiss; Krisztina Bögi; Zsuzsa Schaff
Journal:  Breast Cancer Res       Date:  2005-01-31       Impact factor: 6.466

View more
  21 in total

1.  Dynamic distribution of claudin proteins in pancreatic epithelia undergoing morphogenesis or neoplastic transformation.

Authors:  Joby J Westmoreland; Yiannis Drosos; Jacqueline Kelly; Jianming Ye; Anna L Means; M Kay Washington; Beatriz Sosa-Pineda
Journal:  Dev Dyn       Date:  2012-01-31       Impact factor: 3.780

2.  Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis.

Authors:  A M Szasz; A M Tokes; M Micsinai; T Krenacs; Cs Jakab; L Lukacs; Zs Nemeth; Zs Baranyai; K Dede; L Madaras; J Kulka
Journal:  Clin Exp Metastasis       Date:  2010-10-21       Impact factor: 5.150

3.  Expression of tight junction molecules in breast carcinomas analysed by array PCR and immunohistochemistry.

Authors:  Anna-Mária Tőkés; Attila Marcell Szász; Eva Juhász; Zsuzsa Schaff; László Harsányi; István Arthur Molnár; Zsolt Baranyai; István Besznyák; Attila Zaránd; Ferenc Salamon; Janina Kulka
Journal:  Pathol Oncol Res       Date:  2011-12-23       Impact factor: 3.201

Review 4.  Claudins and alveolar epithelial barrier function in the lung.

Authors:  James A Frank
Journal:  Ann N Y Acad Sci       Date:  2012-06       Impact factor: 5.691

Review 5.  Claudins in cancer: bench to bedside.

Authors:  Makoto Osanai; Akira Takasawa; Masaki Murata; Norimasa Sawada
Journal:  Pflugers Arch       Date:  2016-09-13       Impact factor: 3.657

6.  Claudin 1 in breast tumorigenesis: revelation of a possible novel "claudin high" subset of breast cancers.

Authors:  Yvonne Myal; Etienne Leygue; Anne A Blanchard
Journal:  J Biomed Biotechnol       Date:  2010-05-13

7.  Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype.

Authors:  Anne A Blanchard; George P Skliris; Peter H Watson; Leigh C Murphy; Carla Penner; Ladislav Tomes; Tamara L Young; Etienne Leygue; Yvonne Myal
Journal:  Virchows Arch       Date:  2009-04-23       Impact factor: 4.064

Review 8.  Claudins as biomarkers of differential diagnosis and prognosis of tumors.

Authors:  Olga P Popova; Alla V Kuznetsova; Svetlana Yu Bogomazova; Alexey A Ivanov
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-09       Impact factor: 4.553

9.  RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target.

Authors:  Hitchintan Kaur; Shihong Mao; Quanwen Li; Mansoureh Sameni; Stephen A Krawetz; Bonnie F Sloane; Raymond R Mattingly
Journal:  PLoS One       Date:  2012-12-06       Impact factor: 3.240

Review 10.  Mechanisms involved in breast cancer liver metastasis.

Authors:  Rui Ma; Yili Feng; Shuang Lin; Jiang Chen; Hui Lin; Xiao Liang; Heming Zheng; Xiujun Cai
Journal:  J Transl Med       Date:  2015-02-15       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.